Summary of Purpose
This study will collect data needed to design a treatment trial for patients with Fabry disease using the experimental drug AT-1001. Fabry disease is an inherited metabolic disorder in which an enzyme called alpha-galactosidase A, which normally breaks down fatty substances called glycolipids, is missing or does not function properly. As a result, glycolipids accumulate in various tissues, causing liver, kidney,...Read More →
The following dates are available for this trial. Trial information last updated on 30 June 2017.
|28 Mar 2005||31 Mar 2005||Unavailable||27 Mar 2008||27 Mar 2008||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|